Nerivio, a device that provides acute treatment of migraines, developed by medtech firm Theranica. Photo via Theranica’s website
The device, worn on the upper arm, provides migraine treatment through neuromodulation therapy, altering nerve activity through targeted delivery of a stimulus. The treatment is like “a personalized pain-relief program,” according to the Netanya-based company. It is controlled via app and offers a migraine diary to track treatment sessions and migraine headaches which can be shared with healthcare professionals.
Nerivio, priced at $99, received FDA approval in May and is available in select headache and migraine clinics throughout the US.
“We are honored to be recognized by TIME and thrilled to see Nerivio listed alongside inventions that are shaping the future,” said Alon Iron, CEO and co-founder of Theranica, in a statement. “At Theranica we believe that migraine solutions should be affordable and accessible. We are proud of the non-invasive, low side-effect and drug-free alternative that Nerivio offers and remain dedicated to bringing effective relief to individuals around the world living with migraine.”
Theranica, founded in 2016, raised $35 million in a Series B funding round led by aMoon, Israel’s largest healthcare VC. The company says it is dedicated to developing proprietary electroceuticals that address prevalent medical conditions and diseases.
